Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETON Eton Pharmaceuticals	$3.06 -2.5%	$4.00	$2.42 ▼ $5.81	$78.61M	1.17	69,310 shs	66,832 shs
MLND Millendo Therapeutics	$3.17 -3.1%	$4.00	$0.92 ▼ $16.95	$60.37M	0.48	1.52 million shs	315,091 shs
VBIV VBI Vaccines	$0.63 +3.3%	$0.61	$0.45 ▼ $3.53	$14.92M	1.93	385,926 shs	179,877 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETON Eton Pharmaceuticals	-2.55%	-11.05%	-13.56%	-26.09%	-16.16%
MLND Millendo Therapeutics	-2.39%	-15.06%	-15.50%	-17.01%	+47.96%
VBIV VBI Vaccines	+3.40%	+4.95%	+12.03%	+3.06%	-81.64%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETON Eton Pharmaceuticals	2.3281 of 5 stars	3.5	5.0	0.0	0.0	2.7	0.8	0.0
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	1.0664 of 5 stars	0.0	4.0	0.0	3.9	2.3	0.8	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETON Eton Pharmaceuticals	3.00	Buy	$10.00	226.80% Upside
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETON Eton Pharmaceuticals	$31.64M	2.48	$0.00 per share	998.19	$0.60 per share	5.10
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
VBIV VBI Vaccines	$8.68M	1.72	N/A	N/A	$7.46 per share	0.08

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETON Eton Pharmaceuticals	-$940K	-$0.03	N/A	∞	N/A	-2.96%	-6.21%	-3.17%	5/9/2024 (Estimated)
MLND Millendo Therapeutics	-$36.41M	N/A	0.00	∞	N/A	N/A	-91.03%	-72.44%	N/A
VBIV VBI Vaccines	-$113.30M	-$11.68	N/A	N/A	N/A	-1,403.15%	-199.61%	-58.20%	5/20/2024 (Estimated)

Latest ETON, VBIV, and MLND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/14/2024	Q4 2023	ETON Eton Pharmaceuticals	-$0.04	-$0.09	-$0.05	-$0.09	$7.70 million	$7.31 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETON Eton Pharmaceuticals	N/A	1.65	1.60
MLND Millendo Therapeutics	N/A	6.39	6.39
VBIV VBI Vaccines	N/A	0.65	0.55

Ownership

Institutional Ownership

Company	Institutional Ownership
ETON Eton Pharmaceuticals	27.86%
MLND Millendo Therapeutics	N/A
VBIV VBI Vaccines	12.26%

Insider Ownership

Company	Insider Ownership
ETON Eton Pharmaceuticals	13.16%
MLND Millendo Therapeutics	N/A
VBIV VBI Vaccines	10.35%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ETON Eton Pharmaceuticals	30	25.69 million	22.31 million	Optionable
MLND Millendo Therapeutics	12	19.04 million	N/A	Not Optionable
VBIV VBI Vaccines	190	23.69 million	21.24 million	Optionable

ETON, VBIV, and MLND Headlines

Source	Headline
	VBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.com americanbankingnews.com - April 18 at 2:30 AM
	VBI Vaccines Reports Full Year 2023 Financial Results businesswire.com - April 16 at 8:00 AM
	VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules businesswire.com - April 11 at 4:05 PM
	VBI Vaccines secures $2 million in direct offering investing.com - April 11 at 3:23 PM
	Head-To-Head Survey: VBI Vaccines (NASDAQ:VBIV) and Summit Therapeutics (NASDAQ:SMMT) americanbankingnews.com - April 11 at 2:20 AM
	VBI Vaccines (NASDAQ:VBIV) Coverage Initiated by Analysts at StockNews.com americanbankingnews.com - April 10 at 2:24 AM
	VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules businesswire.com - April 9 at 2:45 PM
	VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma businesswire.com - April 3 at 8:00 AM
	VBI Vaccines expands collaboration with Canadian government msn.com - April 2 at 5:12 PM
	VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform businesswire.com - April 2 at 8:00 AM
	VBI Vaccines Inc. (VBIV) finance.yahoo.com - March 31 at 8:25 AM
	Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results finance.yahoo.com - March 22 at 7:40 AM
	North Carolina biotech inks $30M deal to expand its global pipeline bizjournals.com - February 15 at 3:37 PM
	VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences msn.com - February 14 at 6:34 PM
	Brii Biosciences enters into multiple beneficial deals with VBI Vaccines thepharmaletter.com - February 14 at 1:33 PM
	Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines finance.yahoo.com - February 14 at 1:33 PM
	Why Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket benzinga.com - February 14 at 8:33 AM
	VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences finance.yahoo.com - February 14 at 8:33 AM
	VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences businesswire.com - February 14 at 7:00 AM
	Brii Biosciences To Buy VBI's IP Rights In BRII-179 markets.businessinsider.com - February 13 at 10:32 PM
	Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies prnewswire.com - February 13 at 7:04 PM
	VBI Vaccines Secures Forbearance Agreement Extensions msn.com - February 7 at 9:52 AM
	VBI Vaccines Inc. [VBIV] Investment Guide: What You Need to Know knoxdaily.com - January 2 at 4:56 AM
	VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting finance.yahoo.com - November 20 at 10:15 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Eton Pharmaceuticals

NASDAQ:ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Millendo Therapeutics

NASDAQ:MLND

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

VBI Vaccines

NASDAQ:VBIV

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial